Logo image of LBPH

Longboard Pharmaceuticals Inc (LBPH) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:LBPH - US54300N1037 - Common Stock

59.98 USD
+0.02 (+0.03%)
Last: 11/29/2024, 7:46:54 PM
60.01 USD
+0.03 (+0.05%)
After Hours: 11/29/2024, 7:46:54 PM
Fundamental Rating

3

Overall LBPH gets a fundamental rating of 3 out of 10. We evaluated LBPH against 192 industry peers in the Pharmaceuticals industry. While LBPH has a great health rating, there are worries on its profitability. LBPH does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year LBPH has reported negative net income.
In the past year LBPH has reported a negative cash flow from operations.
LBPH Yearly Net Income VS EBIT VS OCF VS FCFLBPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

LBPH has a Return On Assets (-25.70%) which is comparable to the rest of the industry.
The Return On Equity of LBPH (-27.74%) is better than 67.71% of its industry peers.
Industry RankSector Rank
ROA -25.7%
ROE -27.74%
ROIC N/A
ROA(3y)-65.03%
ROA(5y)N/A
ROE(3y)-77.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LBPH Yearly ROA, ROE, ROICLBPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

LBPH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LBPH Yearly Profit, Operating, Gross MarginsLBPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for LBPH has been increased compared to 1 year ago.
LBPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LBPH Yearly Shares OutstandingLBPH Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 5M 10M 15M 20M
LBPH Yearly Total Debt VS Total AssetsLBPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

An Altman-Z score of 63.60 indicates that LBPH is not in any danger for bankruptcy at the moment.
The Altman-Z score of LBPH (63.60) is better than 96.88% of its industry peers.
There is no outstanding debt for LBPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 63.6
ROIC/WACCN/A
WACCN/A
LBPH Yearly LT Debt VS Equity VS FCFLBPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

LBPH has a Current Ratio of 15.97. This indicates that LBPH is financially healthy and has no problem in meeting its short term obligations.
LBPH has a better Current ratio (15.97) than 88.54% of its industry peers.
A Quick Ratio of 15.97 indicates that LBPH has no problem at all paying its short term obligations.
The Quick ratio of LBPH (15.97) is better than 88.54% of its industry peers.
Industry RankSector Rank
Current Ratio 15.97
Quick Ratio 15.97
LBPH Yearly Current Assets VS Current LiabilitesLBPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

LBPH shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.85%.
EPS 1Y (TTM)7.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 2.83% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y4.61%
EPS Next 2Y-10.02%
EPS Next 3Y-10.5%
EPS Next 5Y2.83%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LBPH Yearly Revenue VS EstimatesLBPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
LBPH Yearly EPS VS EstimatesLBPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4 6 8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LBPH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LBPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LBPH Price Earnings VS Forward Price EarningsLBPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LBPH Per share dataLBPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

LBPH's earnings are expected to decrease with -10.50% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.02%
EPS Next 3Y-10.5%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LBPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Longboard Pharmaceuticals Inc

NASDAQ:LBPH (11/29/2024, 7:46:54 PM)

After market: 60.01 +0.03 (+0.05%)

59.98

+0.02 (+0.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners101.95%
Inst Owner Change0%
Ins Owners0.04%
Ins Owner Change0%
Market Cap2.34B
Revenue(TTM)N/A
Net Income(TTM)-76.34M
Analysts75.38
Price Target65.96 (9.97%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-15.68%
Min EPS beat(2)-24.62%
Max EPS beat(2)-6.75%
EPS beat(4)1
Avg EPS beat(4)-4.45%
Min EPS beat(4)-24.62%
Max EPS beat(4)15.33%
EPS beat(8)4
Avg EPS beat(8)1.23%
EPS beat(12)5
Avg EPS beat(12)-2.26%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.18%
EPS NQ rev (1m)-1.15%
EPS NQ rev (3m)-24.01%
EPS NY rev (1m)-1.17%
EPS NY rev (3m)-7.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.51
P/tB 8.51
EV/EBITDA N/A
EPS(TTM)-2.23
EYN/A
EPS(NY)-2.88
Fwd EYN/A
FCF(TTM)-1.69
FCFYN/A
OCF(TTM)-1.69
OCFYN/A
SpS0
BVpS7.05
TBVpS7.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -25.7%
ROE -27.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-65.03%
ROA(5y)N/A
ROE(3y)-77.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.97
Quick Ratio 15.97
Altman-Z 63.6
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.55%
EPS Next Y4.61%
EPS Next 2Y-10.02%
EPS Next 3Y-10.5%
EPS Next 5Y2.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-65.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-67.64%
EBIT Next 3Y-40.09%
EBIT Next 5Y22.5%
FCF growth 1Y-93.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-93.52%
OCF growth 3YN/A
OCF growth 5YN/A

Longboard Pharmaceuticals Inc / LBPH FAQ

What is the fundamental rating for LBPH stock?

ChartMill assigns a fundamental rating of 3 / 10 to LBPH.


What is the valuation status of Longboard Pharmaceuticals Inc (LBPH) stock?

ChartMill assigns a valuation rating of 0 / 10 to Longboard Pharmaceuticals Inc (LBPH). This can be considered as Overvalued.


How profitable is Longboard Pharmaceuticals Inc (LBPH) stock?

Longboard Pharmaceuticals Inc (LBPH) has a profitability rating of 1 / 10.


Can you provide the financial health for LBPH stock?

The financial health rating of Longboard Pharmaceuticals Inc (LBPH) is 8 / 10.